Baxter International Inc. ($BAX) Stock Forecast: Down 5.0% Today

What is Baxter International Inc.?

Baxter International Inc. (NYSE: BAX) is a global healthcare company specializing in treatments for various medical conditions. The stock recently showed a notable downward trend.

Why is Baxter International Inc. going down?

BAX stock is down 5.0% on Nov 8, 2024 17:42

• Despite exceeding third-quarter expectations in terms of earnings and sales, Baxter faced a stock decline due to reduced gross and operating margins.
• The aftermath of Hurricane Helene is predicted to have a financial impact on Baxter in the short term, potentially causing unease among investors and contributing to the downward movement.
• While a strong demand and favorable pricing environment were projected to boost Baxter's Q3 earnings, complications in the supply chain likely led to increased expenses, influencing the stock's drop.
• Investors, looking beyond revenue and EPS, may have lingering concerns about Baxter's future performance despite surpassing earnings estimates, which has added to the overall bearish sentiment in the market.

BAX Price Chart

BAX Technical Analysis

BAX News

BAX Stock Falls Despite Q3 Earnings & Sales Beat, Margins Decline

Baxter reports better-than-expected third-quarter results. However, the company's gross and operating margins contract. Shares fall.

https://www.zacks.com/stock/news/2367529/bax-stock-falls-despite-q3-earnings-sales-beat-margins-decline

Baxter Expects Hurricane Helene Aftermath To Impact Near-Term Financial Outlook - Baxter Intl ( NYSE:BAX )

Baxter International Inc. BAX reported a third-quarter 2024 adjusted EPS of 80 cents, beating the management guidance of 77 cents to 79 cents and the Wall Street estimate of 78 cents.

https://www.benzinga.com/general/health-care/24/11/41845345/baxter-expects-hurricane-helene-aftermath-to-impact-near-term-financial-outlook

Baxter International ( BAX ) Beats Q3 Earnings Estimates

Baxter (BAX) delivered earnings and revenue surprises of 2.56% and 29.72%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

https://www.zacks.com/stock/news/2367264/baxter-international-bax-beats-q3-earnings-estimates

Strong Demand and Positive Pricing to Drive Baxter's Q3 Earnings

BAX's third-quarter results are likely to benefit from a positive pricing impact and new product launches. However, supply-chain issues are likely to have raised expenses in the quarter.

https://www.zacks.com/stock/news/2364925/strong-demand-and-positive-pricing-to-drive-baxters-q3-earnings

Countdown to Baxter ( BAX ) Q3 Earnings: A Look at Estimates Beyond Revenue and EPS

Evaluate the expected performance of Baxter (BAX) for the quarter ended September 2024, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.

https://www.zacks.com/stock/news/2364238/countdown-to-baxter-bax-q3-earnings-a-look-at-estimates-beyond-revenue-and-eps

Trending Today

Sui ($SUI) Crypto Forecast: Up 5.4% Today

Stellar ($XLM) Crypto Forecast: Up 17.5% Today

Polkadot ($DOT) Crypto Forecast: Up 8.0% Today

XRP ($XRP) Crypto Forecast: Up 24.3% Today

Solana ($SOL) Crypto Forecast: Up 6.8% Today

Ethereum ($ETH) Crypto Forecast: Up 7.5% Today

Cardano ($ADA) Crypto Forecast: Up 10.7% Today

Euro ($EUR/USD) Forex Forecast: Down 1.5% Today

Hedera Hashgraph ($HBAR) Crypto Forecast: Up 5.1% Today

Pepe ($PEPE) Crypto Forecast: Up 9.8% Today

Baxter International Inc. Price History

07.10.2024 - BAX Stock was up 0.3%

• Baxter's stock experienced a strong bullish movement today due to positive expectations regarding its third-quarter earnings.
• The surge in Baxter's stock can be attributed to the anticipated favorable Q3 earnings driven by strong product demand, positive pricing impact, and recent new product introductions.
• Despite possible cost increases from supply chain challenges, investors remain positive about Baxter's future performance, contributing to the upward movement in the stock price.
• Investors are keenly interested in analyzing key metrics and the company's overall performance in addition to traditional revenue and EPS estimates to gain a comprehensive view of Baxter's financial well-being.

08.10.2024 - BAX Stock was down 5.0%

• Despite exceeding third-quarter expectations in terms of earnings and sales, Baxter faced a stock decline due to reduced gross and operating margins.
• The aftermath of Hurricane Helene is predicted to have a financial impact on Baxter in the short term, potentially causing unease among investors and contributing to the downward movement.
• While a strong demand and favorable pricing environment were projected to boost Baxter's Q3 earnings, complications in the supply chain likely led to increased expenses, influencing the stock's drop.
• Investors, looking beyond revenue and EPS, may have lingering concerns about Baxter's future performance despite surpassing earnings estimates, which has added to the overall bearish sentiment in the market.

08.10.2024 - BAX Stock was down 5.1%

• Baxter surpassed expectations in its third-quarter financial performance, exceeding both earnings and sales forecasts. However, the stock declined as gross and operating margins contracted.
• The company's financial outlook was affected by Hurricane Helene's aftermath, raising concerns about its short-term prospects.
• While higher demand and pricing were anticipated to boost earnings, supply-chain challenges increased costs, influencing the stock's negative movement.
• Investors may have reacted poorly to the mix of positive financial results with margin contraction, contributing to the stock's bearish direction.

05.02.2024 - BAX Stock was up 5.1%

• Baxter International is exploring strategic options for its Kidney Care business, potentially signaling a positive restructuring that investors could view favorably.
• The company's participation in various conferences, including the Raymond James 45th Annual Institutional Investors Conference, may have generated investor interest and confidence in Baxter's future.
• The announcement of Baxter's CFO presenting at these conferences likely reassured investors about the company's financial strength and growth opportunities.
• These strategic initiatives and public appearances by Baxter International's executives potentially influenced the stock's bullish movement today.

05.06.2024 - BAX Stock was up 4.6%

• The strong bullish movement of Baxter International today could be linked to the market's positive reception of the company's robust growth across all geographies.
• Despite pandemic-related disruptions affecting sales, investors appear confident in Baxter International's transformational initiatives, which are apparently viewed as promising for future growth.
• The bullish trend indicates that investors are placing more emphasis on the company's growth potential and less on the short-term challenges posed by the ongoing pandemic.

17.06.2024 - BAX Stock was up 5.5%

• The bullish movement in Baxter's stock today can be attributed to the company's recall of the Volara system single-patient use circuit. Despite the recall, investors seem to be reacting positively to the company's proactive approach to ensuring patient safety and addressing the issue promptly.
• The rise in Baxter's shares could also be influenced by the recent stability shown by the stock after a previous decline in the first half of 2024. Investors may be gaining confidence in the company's ability to navigate challenges and maintain a strong market position.
• Overall, Baxter's stock performance reflects a mix of short-term positive momentum from addressing the recall issue and long-term investor sentiment regarding the company's resilience and potential for growth in the healthcare sector.

13.07.2024 - BAX Stock was down 6.7%

• The recent divestment of Baxter International's renal care and acute therapies business may have sparked concerns among investors, impacting the stock's performance negatively.
• Despite surpassing Q2 expectations and adjusting its outlook, the decision to divest its kidney care unit could have prompted a tepid market reaction, creating uncertainty about the company's financial future.
• External factors like Home Depot's disappointing outlook and escalating tensions in the Middle East might have compounded the bearish market sentiment, affecting Baxter International's stock price as well.
• Investor apprehension regarding Baxter's growth prospects post-divestiture led to a sell-off in the stock, with lingering doubts about its ability to sustain growth.

13.07.2024 - BAX Stock was down 6.4%

• The company faced a sharp decline in its stock value after announcing the sale of its Kidney Care unit, Vantive, to The Carlyle Group for $3.8 billion.
• Market sentiment turned negative following this announcement, with concerns arising about the potential impact of divesting such a significant segment.
• Investors seem unsure about Baxter International Inc.'s future growth trajectory without its kidney care division, prompting a selloff of shares.
• While the sale could signify a strategic realignment for Baxter, the initial market reaction appears cautious and doubtful.

13.07.2024 - BAX Stock was down 7.2%

• Baxter International's decision to sell off its renal care and acute therapies division indicates a shift in its focus, potentially sparking concerns among investors regarding future growth.
• The acquisition of Baxter's kidney-care spinoff Vantive by Carlyle Group for $3.8 billion could be causing uncertainty among investors about its impact on Baxter's finances and overall business strategy.
• Factors such as negative guidance from Home Depot and escalating tensions in the Middle East are influencing the broader market sentiment, potentially contributing to the downturn in Baxter's stock.
• In light of these strategic changes and external market conditions, investors might be reassessing their positions in Baxter International, resulting in downward pressure on the stock.

06.07.2024 - BAX Stock was up 5.4%

• Baxter International Inc. experienced a strong bullish movement today following its second-quarter earnings report.
• The company beat earnings and revenue estimates for Q2, with sales exceeding expectations and growing across all segments.
• Baxter raised its earnings, adjusted earnings, and sales growth guidance for the full-year 2024, indicating strong confidence in its future performance.
• The positive market movement can be attributed to the company's strong financial results and optimistic outlook, showcasing its ability to deliver value to shareholders and drive growth in the healthcare sector.

06.07.2024 - BAX Stock was up 6.9%

• Baxter International Inc. (BAX) experienced a strong bullish movement today.
• The bullish market movement can be attributed to Baxter's better-than-expected second-quarter earnings and sales, reflecting solid demand for its medically essential products.
• The company beat analyst estimates for both earnings per share (EPS) and revenue for Q2 2024, leading to a positive outlook and an increase in its full-year EPS guidance.
• The strong performance across all segments, particularly in pharmaceuticals, contributed to exceeding sales growth expectations, driving investor confidence and pushing the stock price higher.

06.07.2024 - BAX Stock was up 7.2%

• Baxter International Inc. (BAX) announced robust financial results for the second quarter, prompting an increase in its earnings, adjusted earnings, and sales growth guidance for the entire fiscal year of 2024.
• The company's Q2 earnings performance exhibited improvement compared to the corresponding period last year, signaling positive growth and overall performance.
• Despite the contrarian investment approach discussed elsewhere, which emphasizes seeking undervalued assets, Baxter's solid fundamentals and positive guidance have evidently rewarded investors with considerable returns.
• The optimistic sentiment surrounding MedTech stocks, including Baxter International Inc. (BAX), in anticipation of their earnings announcements, also contributed to the stock's bullish trajectory today.